Authors


Lawrence P.L. IU

Latest:

Outer retinal layer thickness predicts visual acuity in diabetic macular oedema

Diabetes mellitus is a common health problem in developed countries, with diabetic macular oedema (DMO) being a major cause of visual loss. A variety of treatment modalities for DMO are available including laser, steroid and intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.


Dr Peter Karth

Latest:

Diagnosing and treating MacTel degenerative retinal disease

Idiopathic macular telangiectasia (MacTel) is bilateral condition characterised by ectatic capillaries of the macula and atrophy of the neurosensory retina. Familiarity with the distinctive intraretinal cavitation on SD-OCT in type 2, the most common type, is key for correct diagnosis.


Ian Y.H. Wong

Latest:

Outer retinal layer thickness predicts visual acuity in diabetic macular oedema

Diabetes mellitus is a common health problem in developed countries, with diabetic macular oedema (DMO) being a major cause of visual loss. A variety of treatment modalities for DMO are available including laser, steroid and intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.


OTE Staff Reports

Latest:

Prevent Blindness observes inherited retinal disease genetic testing week May 16-22

Prevent Blindness dedicates the third week of May to raising awareness of the benefit of genetic testing, variety of retinal diseases, and available resources.


Lisa Stewart

Latest:

2023: What awaits ophthalmology in the year ahead

As we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.


Michelle Dalton, ELS

Latest:

Considering YAG vitreolysis for persistent vitreous floaters

Study evaluates the impact of surgical procedure on visual outcomes in patients


Joshua Mali, MD

Latest:

2023: Top 5 predictions for ophthalmology in the New Year

Joshua Mali, MD, offers his top 5 prognostications for 2023.



Ophthalmology Times Staff Reports

Latest:

AAO 2020: Bringing high-level content to a virtual audience

Anne L. Coleman, MD, president of the American Academy of Ophthalmology, offers a preview of its virtual 2020 annual meeting.


Cheryl Guttman Krader, BS, Pharm

Latest:

Elucidating Alzheimer disease pathophysiology

Study of subjects with rare inherited form of AD shows increased retinal capillary perfusion during the presymptomatic stage.


Lynda Enoch Charters
Lynda Charters

Latest:

COPHy 2023: New restorative therapies

In a keynote lecture at the 14th Annual Congress on Controversies in Ophthalmology in Lisbon, Hendrik Scholl, MD, co-founder and director of the Institute of Molecular and Clinical Ophthalmology Basel, discussed its mission to unravel the mysteries of vision and human eye disease.


Louise Gagnon

Latest:

Treating AMD and DME with faricimab: A therapy with lower treatment burden

According to physician, this therapeutic may prove to be a treatment option for these diseases.



Beth Thomas Hertz

Latest:

ARVO heads north to Vancouver for 2019 annual meeting

‘From the Bench to Bedside and Back’ is focal point for this year’s conference


Laird Harrison

Latest:

Face-down positioning better after detached retina repair

Face-down positioning is associated with a reduction in certain complications following macula-involving retinal displacement (RD) repair, according to researchers.


Pravin U. Dugel, MD

Latest:

Novel brolucizumab fosters as real-world alternative for nAMD

Topline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.



Nancy Groves

Latest:

Tocilizumab effective for managing posterior segment inflammation

Improvement in visual acuity, central retinal thickness, vitreous haze reported at 6 months



Cheryl Guttman Krader, BS, Pharm

Latest:

Survey: Retina specialists see need for alternative treatments for macular edema associated with noninfectious uveitis

Survey respondents point to a perceived gap in treatments for uveitic macular edema, document interest in suprachoroidal drug delivery.


Ophthalmology Times Staff Reports

Latest:

2023: What awaits ophthalmology in the year ahead

As we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.


Rose Schneider Krivich

Latest:

Anti-seizure drug gets boxed warning for eye damage risks

The FDA has approved changes to the drug label of the anti-seizure drug ezogabine (Potiga), underscoring risks of abnormalities to the retina in the eye, potential vision loss, and skin discoloration-all of which may become permanent.


Michelle Dalton

Latest:

Migraines and retinal perfusion: A headache for physicians, patients

Optical coherence tomography angiography can detect microcirculatory disturbances during acute attacks.


Vanessa Caceres

Latest:

PALADIN subset finds improvement after 12 months with intravitreal implant

Among a subset of patients in the phase IV PALADIN study, there was improved visual acuity, improved macular thickness, and reduced treatment burden among patients treated with the intravitreal fluocinolone acetonide 0.2 µg (Iluvien implant) for DME.


Dr Fahd Quhill

Latest:

Intravitreal implant could bring significant cost savings to NHS England

A study has revealed that a budgetary saving per treated patient with the fluocinolone acetonide implant (Iluvien) versus ranibizumab (Lucentis) could lead to a significant cost-saving to NHS England.


Nicola O'Connell

Latest:

Moorfields research provides hope for choroideremia cure

Preliminary research has shown that ataluren is effective in overriding the nonsense mutation in choroideremia patients, however, further research is needed.


Thomas A. Albini, MD

Latest:

Case #2: Impressions and Clinical Insights

A retina specialist discusses impressions and key take away points from patient case.




© 2023 MJH Life Sciences

All rights reserved.